Description
This session will be put on by the Running Medicine Member Community and will feature residents in training who are doing active research in running medicine and/or are passionate about running medicine and are well-versed in related topics. The goal of the session is to discuss updates in the literature, the current state of running medicine research, get to know up and coming running medicine specialists, and provide the opportunity for select trainees to practice oral presentation skills and networking within the national community. Presentations will cover topics in running medicine such as sun protection and skin cancer risk in endurance athletes, exertional leg pain, and community outreach programming to provide pertinent health education to high school runners.
Learning Objectives
After completing this live activity, the participant should be able to:
- Identify gaps in sunscreen adherence and protective behaviors in training and competition settings in endurance athletes.
- Describe one method for adolescent runner health education for injury prevention and health optimization.
- Define exertional leg pain, differential diagnosis, and identify the potential for under diagnosis of popliteal artery entrapment syndrome.
- Provide a networking opportunity for running medicine enthusiastic trainees and sports medicine physicians.
Accreditation Statement
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Credit Designation
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this live activityfor a maximum of 0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, AAPM&R requires all individuals who are in a position to affect the strategic direction of AAPM&R and/or control the content of an educational activity to disclose all financial relationships with any ineligible company within the last 24 months. The ACCME defines an “ineligible company” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosures are made in written form prior to the start of the educational activity, and any potential conflicts of interest that exist are mitigated prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to affect the strategic direction of AAPM&R and/or control content and their disclosed financial relationships are listed below.
No other planners, faculty, or individuals in control of content disclosed any relevant financial relationships.
Principle Faculty
Name, Credential(s): Company Name, Nature of financial relationship;
Sara Raiser MD, FAAPMR - Nothing to disclose
Andrew Nowak MD, FAAPMR - Nothing to disclose
Jacob Goforth MD - Nothing to disclose
Riley Barnes MD - Nothing to disclose
Abigail Bideaux MD - Nothing to disclose
AAPM&R Medical Education Committee
Name, Credential(s): Company Name, Nature of financial relationship
Rachel Brakke Holman, MD - Nothing to Disclose
Sarah M. Eickmeyer, MD - Nothing to Disclose
Chelsea D. Frost, MD, MS - Nothing to Disclose
David J. Haustein, MBA,MD,MBA - Relationships to Disclose
Sarah K. Hwang, MD - Nothing to Disclose
Ravi E. Kasi, MD - Nothing to Disclose
Caroline Pupke, DO - Nothing to Disclose
Monica E. Rho, MD - Nothing to Disclose
McCasey R. Smith, MD - Nothing to Disclose
Jennifer A. Soo Hoo, MD - Nothing to Disclose
Brionn K. Tonkin, MD - Nothing to Disclose
Stephanie Tow, MD - Nothing to Disclose
Justin L. Weppner, DO - Nothing to Disclose
Alexandra G. Wolfe, DO - Nothing to Disclose
FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.